Abstract:A glucose‐responsive hydrogel, Cu‐PEI/siMyD88@GEMA‐Con A (CSGC), is developed to deliver Cu‐PEI/siMyD88 NPs to the retinal pigment epithelium (RPE) (Figure a). Cu‐PEI acts as an antioxidant, reducing ROS and inhibiting RPE cells' pyroptosis, thus blocking primary blood‐retinal barrier (BRB) injury. Simultaneously, siMyD88 inhibits MyD88 expression, reducing IL‐18 and vascular endothelial growth factor (VEGF) expression, and enhancing tight junction protein expression, thus blocking secondary BRB injury (Figure b). In summary, the CSGC hydrogel efficiently remodels retinal microenvironment (RME), representing a promising diabetic retinopathy (DR) therapy. Current diabetic retinopathy (DR) treatment involves blood glucose regulation combined with laser photocoagulation or intravitreal injection of vascular endothelial growth factor (VEGF) antibodies. However, due to the complex pathogenesis and cross‐interference of multiple biochemical pathways, these interventions cannot block disease progression. Recognizing the critical role of the retinal microenvironment (RME) in DR, it is hypothesized that reshaping the RME by simultaneously inhibiting primary and secondary blood–retinal barrier (BRB) injury can attenuate DR. For this, a glucose‐responsive hydrogel named Cu‐PEI/siMyD88@GEMA‐Con A (CSGC) is developed that effectively delivers Cu‐PEI/siMyD88 nanoparticles (NPs) to the retinal pigment epithelium (RPE). The Cu‐PEI NPs act as antioxidant enzymes, scavenging ROS and inhibiting RPE pyroptosis, ultimately blocking primary BRB injury by reducing microglial activation and Th1 differentiation. Simultaneously, MyD88 expression silence in combination with the Cu‐PEI NPs decreases IL‐18 production, synergistically reduces VEGF levels, and enhances tight junction proteins expression, thus blocking secondary BRB injury. In summary, via remodeling the RME, the CSGC hydrogel has the potential to disrupt the detrimental cycle of cross‐interference between primary and secondary BRB injury, providing a promising therapeutic strategy for DR.

Repairing the Retinal Ischemic Microenvironment with an Engineered Exosome-Loaded Dehydroepiandrosterone Peptide Hydrogel

Functional Engineered Exosomes Mitigate Pathological Ischemic Retinopathy through a Dual Strategy of Inflammatory Microenvironment Modulation and Angiogenic Factor Control

Injectable, antioxidative, and loaded with exosomes/Liproxstatin-1 hydrogel as a potential treatment for retinal ischemia–reperfusion by inhibiting ferroptosis and apoptosis

Engineered Extracellular Vesicles for Delivery of an IL-1 Receptor Antagonist Promote Targeted Repair of Retinal Degeneration

Progress in Silk Fibroin Based Composite Scaffold/Hydrogel: Silk Fibroin/PEG Hydrogel for the RPE Regeneration a Promising Biomaterial for Clinical Application

Acellularized Uvea Hydrogel As Novel Injectable Platform for Cell‐based Delivering Treatment of Retinal Degeneration and Optimizing Retinal Organoids Inducible System

Enhanced proliferation and differentiation of retinal progenitor cells through a self-healing injectable hydrogel.

Effective protection of photoreceptors using an inflammation-responsive hydrogel to attenuate outer retinal degeneration

Retinal Microenvironment‐Protected Rhein‐GFFYE Nanofibers Attenuate Retinal Ischemia‐Reperfusion Injury via Inhibiting Oxidative Stress and Regulating Microglial/Macrophage M1/M2 Polarization

A Glucose‐Responsive Hydrogel Inhibits Primary and Secondary BRB Injury for Retinal Microenvironment Remodeling in Diabetic Retinopathy

Mesenchymal Stem Cells Derived Extracellular Vesicles Modified-Plga Electrospinning Nanofibrous Scaffolds for Corneal and Retinal Repair

RPE-derived exosomes rescue the photoreceptors during retina degeneration: an intraocular approach to deliver exosomes into the subretinal space

Compounding engineered mesenchymal stem cell-derived exosomes: A potential rescue strategy for retinal degeneration

Effectively Intervening Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells with a Combination of ROCK and TGF-β Signaling Inhibitors.

Human Retinal Progenitor Cells Derived Small Extracellular Vesicles Delay Retinal Degeneration: A Paradigm for Cell-free Therapy

Intravitreal Administration of Retinal Organoids-Derived Exosomes Alleviates Photoreceptor Degeneration in Royal College of Surgeons Rats by Targeting the Mitogen-Activated Protein Kinase Pathway

3D hypoxia-mimicking and anti-synechia hydrogel enabling promoted neovascularization for renal injury repair and regeneration

An injectable exosome-loaded hyaluronic acid-polylysine hydrogel for cardiac repair via modulating oxidative stress and the inflammatory microenvironment

Exosomes-loaded thermosensitive hydrogels for corneal epithelium and stroma regeneration

Co-grafts of Human Embryonic Stem Cell Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient Retinal Degenerate Royal College of Surgeons Rats

Restoring Cardiac Functions after Myocardial Infarction–Ischemia/Reperfusion via an Exosome Anchoring Conductive Hydrogel